These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16956694)

  • 1. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
    Han SW; Kim TY; Lee KH; Hwang PG; Jeon YK; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ
    Lung Cancer; 2006 Nov; 54(2):201-7. PubMed ID: 16956694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
    Han Y; Xu JM; Duan HQ; Zhang Y; Liu XQ; Zhang JS
    Chin J Cancer; 2010 Jan; 29(1):69-75. PubMed ID: 20038315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma.
    Toyooka S; Takano T; Kosaka T; Hotta K; Matsuo K; Ichihara S; Fujiwara Y; Soh J; Otani H; Kiura K; Aoe K; Yatabe Y; Ohe Y; Mitsudomi T; Date H
    Cancer Sci; 2008 Feb; 99(2):303-8. PubMed ID: 18271929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
    Shukuya T; Takahashi T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Takahashi K; Yamamoto N
    Cancer Sci; 2011 May; 102(5):1032-7. PubMed ID: 21272159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M
    Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
    Kimura H; Kasahara K; Shibata K; Sone T; Yoshimoto A; Kita T; Ichikawa Y; Waseda Y; Watanabe K; Shiarasaki H; Ishiura Y; Mizuguchi M; Nakatsumi Y; Kashii T; Kobayashi M; Kunitoh H; Tamura T; Nishio K; Fujimura M; Nakao S
    J Thorac Oncol; 2006 Mar; 1(3):260-7. PubMed ID: 17409866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
    Taron M; Ichinose Y; Rosell R; Mok T; Massuti B; Zamora L; Mate JL; Manegold C; Ono M; Queralt C; Jahan T; Sanchez JJ; Sanchez-Ronco M; Hsue V; Jablons D; Sanchez JM; Moran T
    Clin Cancer Res; 2005 Aug; 11(16):5878-85. PubMed ID: 16115929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
    Takeda M; Okamoto I; Nakagawa K
    J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.
    Sone T; Kasahara K; Kimura H; Nishio K; Mizuguchi M; Nakatsumi Y; Shibata K; Waseda Y; Fujimura M; Nakao S
    Cancer; 2007 May; 109(9):1836-44. PubMed ID: 17387741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
    Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
    Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
    Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A
    J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
    Tokumo M; Toyooka S; Kiura K; Shigematsu H; Tomii K; Aoe M; Ichimura K; Tsuda T; Yano M; Tsukuda K; Tabata M; Ueoka H; Tanimoto M; Date H; Gazdar AF; Shimizu N
    Clin Cancer Res; 2005 Feb; 11(3):1167-73. PubMed ID: 15709185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
    Yang CH; Shih JY; Chen KC; Yu CJ; Yang TY; Lin CP; Su WP; Gow CH; Hsu C; Chang GC; Yang PC
    Cancer; 2006 Oct; 107(8):1873-82. PubMed ID: 16989002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
    Zhang XT; Li LY; Mu XL; Cui QC; Chang XY; Song W; Wang SL; Wang MZ; Zhong W; Zhang L
    Ann Oncol; 2005 Aug; 16(8):1334-42. PubMed ID: 15956035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of the response to gefitinib in refractory non-small cell lung cancer.
    Kim KS; Jeong JY; Kim YC; Na KJ; Kim YH; Ahn SJ; Baek SM; Park CS; Park CM; Kim YI; Lim SC; Park KO
    Clin Cancer Res; 2005 Mar; 11(6):2244-51. PubMed ID: 15788673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
    Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
    Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.